English | 简体中文 | 繁體中文 | 한국어 | 日本語
Thursday, 7 November 2024, 11:40 JST
Share:
    

Source: NEC Corporation
NEC and NEC Bio publish foundational work on T Cell Receptor engineering using proprietary generative AI at the Society for Immunotherapy of Cancer annual meeting
NEC Bio, NEC's biotech branch, puts generative AI in practice and unveils successful modification of T cell receptors, a potential game changer in the world of TCR-based therapies.

TOKYO, Nov 7, 2024 - (JCN Newswire) - Utilizing proprietary generative AI technology, NEC Bio has successfully modified T cell receptors (TCRs) to increase their efficacy. This achievement marks a major step forward in drug development and personalized medicine since prediction and engineering of TCR sequences that are able to bind to specific target sequences remains a major challenge in the field. The technology is being presented as a poster at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Houston, Texas, from November 6 to 10, 2024.

Advancing Personalized Cancer Treatment

NEC Bio’s mission is to develop groundbreaking therapies for patients around the globe using advanced cutting edge AI technologies. TCR-based therapies use the high binding affinity of TCR to bind to defined cancer cells and destruct them using various strategies. One major hurdle in the development of TCR therapies is the difficulty in identifying TCR sequences that will bind specifically to given target sequences. Conventionally, this involves a labor-intensive process of lab screening, trying to isolate the necessary TCR from human donor cells.Motoo Nishihara, Corporate Executive Vice President and CTO of NEC, said: "We are incredibly proud to announce our work on T Cell Receptor engineering using our proprietary generative AI, presented at the Society for Immunotherapy of Cancer annual meeting. This initiative emphasizes our dedication to advancing immunotherapy and highlights the transformative potential of our technology. We are excited about the future and the significant impact our innovations will have on the field of cancer treatment. This technology makes our portfolio stronger and serves our mission to bring AI-led innovative medicine to patients globally."

About the technology

The AI model developed at NEC Bio utilizes generative AI and domain-specific large language models (LLMs) for creating novel TCRs with high efficacy. Given a target peptide, the AI model can generate high affinity TCR sequences for targeted therapy based on knowledge from machine learning on physio-chemical TCR interactions. The AI was benchmarked on public datasets and achieved better performance than baseline methods. The AI-designed TCRs were shown to have enhanced TCR activities in cell-based assays conducted in collaboration with Aichi Cancer Center.Building on this success, NEC Bio will expand the application of its generative AI technology to design TCRs for various oncodriver targets, antibodies for specific targets, immunoproteins, DNA constructs, mRNA constructs, and more. This broad application spectrum highlights NEC Bio’s commitment to pushing the boundaries of what is possible in drug design and development.

SITC poster details

NEC Bio is presenting this technology in a poster at the Society for Immunotherapy of Cancer (SITC), in Houston, Texas, from November 6 to 10, 2024. Details on the poster are below:Poster title: Design of Enhanced TCRs Against Cancer Antigens Using an AI SystemAuthors: Martin Renqiang Min, Tianxiao Li, Kazuhide Onoguchi, Daiki Mori, Jonathan Warrell, Pierre Machart, Anja Moesch, Andrea Meiser, Ivy Grace Pait, Ayako Okamura, Daisuke Muraoka, Hirokazu Matsushita, Kaidre BendjamaPoster Number: 1230Date: November 7, 2024The poster can be found here: Home | NEC Bio B.V

About NEC Corporation

NEC Corporation has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of “Orchestrating a brighter world.” NEC enables businesses and communities to adapt to rapid changes taking place in both society and the market as it provides for the social values of safety, security, fairness and efficiency to promote a more sustainable world where everyone has the chance to reach their full potential.For more information, visit NEC at https://www.nec.com.

About NEC Bio

NEC Bio, the biotech arm of NEC Corporation, is based in the Netherlands and dedicated to the development of innovative biotechnological solutions to tackle some of the most pressing health challenges. NEC Bio's research and development efforts are focused on creating personalized therapies that improve the quality of life for patients worldwide. NEC OncoImmunity in Oslo, Norway, is also a subsidiary of NEC Bio. For more information, visit Home | NEC Bio B.V (nec-bio.com)

Media contact:
7-1, Shiba 5-chome,
Minato-ku, Tokyo 108-8001, Japan
Phone: +81-3-3454-1111



Topic: Press release summary
Source: NEC Corporation

Sectors: BioTech
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 
NEC Corporation Links

http://www.nec.com

https://www.facebook.com/nec.global/

https://twitter.com/NEC_corp

https://www.youtube.com/user/NECglobalOfficial

https://www.linkedin.com/company/nec/

NEC Corporation Related News
Monday, 28 October 2024, 17:05 JST
NEC launches new end to end private 5G solution with Cisco
Friday, 25 October 2024, 21:59 JST
Joint proposal by NTT, KDDI, Fujitsu, NEC, and Rakuten Mobile adopted as Japan's Ministry of Internal Affairs and Communications/NICT's "Innovative ICT Fund Projects for Beyond 5G/6G" for social implementation and overseas expansion oriented strategic program (common infrastructure technology establishment)
2024年10月22日 14時45分 JST
NTT、KDDI、富士通、NEC、楽天モバイルによる共同提案が総務省/NICTの「革新的情報通信技術(Beyond 5G(6G))基金事業」社会実装・海外展開志向型戦略的プログラム(共通基盤技術確立型)に採択
Thursday, 17 October 2024, 11:38 JST
Regarding the transfer of sales functions related to NEC-brand PCs for commercial customers
Wednesday, 16 October 2024, 12:35 JST
Fujitsu to combat fake news in collaboration with leading Japanese organizations
More news >>
Copyright © 2024 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575